LOGO AR

Pill imprint LOGO AR has been identified as Acarbose 25 mg.

Acarbose is used in the treatment of diabetes, type 2 and belongs to the drug class alpha-glucosidase inhibitors. There is no proven risk in humans during pregnancy.

Acarbose 25 mg is not subject to the Controlled Substances Act.
See also related documents.

Acarbose Images

Acarbose

Imprint:: LOGO
AR
Strength:: 25 mg
Color:: White
Shape:: Round
Availability:: Prescription only
Inactive Ingredients:: starch
microcrystalline cellulose
magnesium stearate
croscarmellose sodium
Drug Class:: Alpha-glucosidase inhibitors
Pregnancy Category:: B - No proven risk in humans
CSA Schedule:: N - Not a controlled drug
Manufacturer:: Cobalt Laboratories Inc
National Drug Code (NDC):: 16252-0523

View Drug Details Print Page

More Acarbose resources

Acarbose (Wolters Kluwer)
acarbose (Cerner Multum)
acarbose (Micromedex) - Includes Dosage Information
Acarbose (AHFS DI)
Acarbose (FDA)
Acarbose (Wolters Kluwer)

Acarbose is associated with the treatment of:

Diabetes, Type 2

Search Again

Search by Imprint, Shape or Color

Note: All fields optional. Use the pill finder to identify medications by visual appearance or name.

Imprint:
Color:
Shape:

Sign In or Register

Forgot password?

Related Acarbose Information

Availability Prescription only

CSA Schedule Not a controlled drug

Pregnancy Category No proven risk in humans

Approval History Drug history at FDA

Reviews

Average User Rating

No Reviews - Be the first!

Not Rated - Be the first!

Related Pages

Drug Class

Alpha-glucosidase inhibitors

Recently Approved

Mitosol
Mitosol (mitomycin) is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery.
Sklice
Sklice (ivermectin) Lotion is a pediculicide indicated for the topical treatment of head lice infestations in ...
Jentadueto
Jentadueto (linagliptin and metformin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide ...
Kalydeco
Kalydeco (ivacaftor) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated ...
Erivedge
Erivedge (vismodegib) is a hedgehog pathway inhibitor for the treatment of patients with advanced basal cell ...

More...

FDA Consumer Updates

More FDA Updates...

Related News and Articles

4 New Genes Linked to Type 2 Diabetes 9 February 2012
Four new genes associated with type 2 diabetes have been identified by researchers, who also pinpointed six independent diabetes-associated gene variants at...
Short Breaks During Exercise OK for Diabetes Control: Study 8 February 2012
Taking short breaks while exercising, or "intermittent" exercise, is an effective way to improve insulin sensitivity and blood sugar control in people with...
Pancreas May 'Taste' Fructose, Hinting at Links to Diabetes 6 February 2012
New research shows that the pancreas has sweet-taste receptors -- like those found on the tongue -- that can "taste" fructose. Fructose is a common ingredient...
Metformin Preferred Drug for Type 2 Diabetes, Experts Say 6 February 2012
When it comes to the treatment of type 2 diabetes, the first line of defense is lifestyle changes such as losing weight and exercising more often. But, if...
Diabetes Takes Toll on Women's Hearing: Study 3 February 2012
Diabetes is associated with hearing loss in women, especially if the blood sugar disease isn't well-controlled, new research indicates. The study, done by...

Get Updates by Email

Email me about acarbose systemic:

Did you find this page helpful? Yes No

Support

About Drugs.com

Your Privacy

Follow us on: Google+ Facebook Twitter

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines & natural products. This material is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.

Data sources include Micromedex™ (updated Jan 27th, 2011), Cerner Multum™ (updated Jan 3rd, 2012), Wolters Kluwer™ (updated Jan 31st, 2012) and others.
To view content sources and attributions, refer to our editorial policy.

We comply with the HONcode standard for trustworthy health information.
Verify here

Terms of Use · Privacy Policy